Effectiveness and Safety Study of the Iovera Device for the Temporary Reduction in the Appearance of Forehead Wrinkles

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

85 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-09-30

Study Completion Date

2014-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate the effectiveness and safety of the iovera device for the temporary reduction in the appearance of forehead wrinkles.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Study Evaluating the Treatment of Hyperdynamic Forehead Wrinkles

NCT01984619

Wrinkles

COMPLETED

Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

NCT01940991

Skin Aging

COMPLETED PHASE2

Evaluation of the Safety and Performance of Epicare for the Treatment of Periorbital Wrinkles

NCT07114562

Periorbital Wrinkles

NOT_YET_RECRUITING NA

Study to Evaluate the Safety and Efficacy of the Cytrellis Micro-Coring Device for the Treatment of Moderate to Severe Facial Wrinkles

NCT03793348

Wrinkle

UNKNOWN NA

Post Market Study To Collect Efficacy Data For The Treatment Of Wrinkles With A Radiofrequency Device

NCT05096247

Wrinkle Benign Pigmented Lesions Benign Vascular Lesions

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Forehead Wrinkles

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Immediate Treatment with iovera

Immediate treatment with iovera

Group Type EXPERIMENTAL

iovera

Intervention Type DEVICE

Delayed Treatment with iovera

Group Type ACTIVE_COMPARATOR

iovera

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

iovera

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 to 65 years
* Subject has a forehead wrinkle rating by the Investigator/designee of at least "2" in full contraction on the 5-point Wrinkle Scale (5WS) as rated by the study Investigator, which, upon physical manipulation/separation of the skin, demonstrates a reduction in wrinkle severity
* Subject has a glabella wrinkle rating by the Investigator/designee of at least "1" in full contraction on the 5-point Glabella Scale (5GS)
* Subject has at least a 2 point difference between resting and dynamic forehead wrinkle scores using the 5-point Wrinkle Scale (5WS) as rated by the Investigator/designee
* Subject has Fitzpatrick Skin Type I, II, III, or IV (see Error! Reference source not found.)
* Subject understands and commits to comply with study requirements
* Subject is in good general health and free of any condition that could impair either complete study participation or evaluation of forehead wrinkle rating
* Subject is willing and able to give written informed consent

Exclusion Criteria

* Subject has a clotting disorder or coagulopathy that requires regular use of an anticoagulant and/or antiplatelet therapy (e.g., warfarin, clopidogrel, etc.)
* Subject has used aspirin or any non-steroidal anti-inflammatory drugs (NSAIDs) within seven (7) days prior to screening or use of the device
* Subject has had prior surgery that alters the subcutaneous anatomy of the target treatment sites
* Subject has undergone another surgical cosmetic procedure or botulinum toxin injection at or above the level of the zygoma (cheekbones) within the past six (6) months prior to screening
* Subject has a resting wrinkle score of "3" or higher on the 5WS as rated by the study Investigator
* Subject actively elevates forehead during rest
* Subject has been treated with any fillers listed in Error! Reference source not found. in the temple or forehead area in the time intervals specified prior to screening
* Subject has any of the following conditions:

* Dermatochalasis with \<2mm lid margin when looking straight ahead
* Excessive skin laxity/skin aging
* Asymmetry in the upper face
* History of facial nerve palsy
* Eyebrow or eyelid ptosis
* History of neuromuscular disorder
* Chronic dry eye symptoms
* Allergy or intolerance to local anesthetic agents (e.g., Lidocaine)
* Use of narcotic medications for a chronic pain condition
* Other clinically significant local skin condition (e.g., skin infection) at target treatment site
* Any physical or psychiatric condition that in the Investigator's opinion would prevent treatment or adequate study participation
* Chronic medical condition that in the Investigator's opinion would affect study participation (such as diabetes, hepatitis, HIV, etc.)
* Known diagnosis of cryoglobulinemia, paroxysmal cold hemoglobinuria, or cold urticaria
* Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in the opinion of the Investigator
* Fitzpatrick Skin Type V or VI (see Table 3)
* Subject currently enrolled in an investigational drug, biologic or device study that could affect the safety or effectiveness of wrinkle treatment

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes